[
    [
        {
            "time": "2020-12-07",
            "original_text": "复星医药阿达木单抗获批 三足鼎立市场格局或被打破",
            "features": {
                "keywords": [
                    "复星医药",
                    "阿达木单抗",
                    "获批",
                    "市场格局"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "复星医药阿达木单抗获批 三足鼎立市场格局或被打破",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-12-07",
            "original_text": "新冠疫情期间 mRNA疫苗投资 沃森生物之后智飞生物也出手",
            "features": {
                "keywords": [
                    "新冠",
                    "mRNA疫苗",
                    "沃森生物",
                    "智飞生物"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新冠疫情期间 mRNA疫苗投资 沃森生物之后智飞生物也出手",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-12-07",
            "original_text": "电报|复宏汉霖：阿达木单抗汉达远获批上市自动纳入医保",
            "features": {
                "keywords": [
                    "复宏汉霖",
                    "阿达木单抗",
                    "汉达远",
                    "获批",
                    "医保"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "电报|复宏汉霖：阿达木单抗汉达远获批上市自动纳入医保",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-12-07",
            "original_text": "汉达远获批上市 复星医药开启自身免疫疾病慢病管理新时代",
            "features": {
                "keywords": [
                    "汉达远",
                    "获批",
                    "复星医药",
                    "慢病管理"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "汉达远获批上市 复星医药开启自身免疫疾病慢病管理新时代",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-12-07",
            "original_text": "晚间重要公告2020年12月7日星期一",
            "features": {
                "keywords": [
                    "晚间公告",
                    "2020-12-07"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "晚间重要公告2020年12月7日星期一",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2020-12-07",
            "original_text": "复星医药：阿达木单抗注射液上市注册申请获批",
            "features": {
                "keywords": [
                    "复星医药",
                    "阿达木单抗",
                    "注射液",
                    "获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "复星医药：阿达木单抗注射液上市注册申请获批",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-12-07",
            "original_text": "【异动股】生物疫苗板块低开，沃森生物(300142-CN)跌16.91%",
            "features": {
                "keywords": [
                    "生物疫苗",
                    "沃森生物",
                    "低开",
                    "跌幅"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【异动股】生物疫苗板块低开，沃森生物(300142-CN)跌16.91%",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-12-04",
            "original_text": "A股融资融券日报：两融余额减少13.24亿元（12月4日）",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额",
                    "减少"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额减少13.24亿元（12月4日）",
                "Correlation": 4,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]